Applied Therapeutics, Inc. (APLT) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
545 5TH AVENUE, SUITE 1400 NEW YORK, NY 10017 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 22,900 | 30,600 | 47,400 | 67,700 | 55,700 | 80,800 | |||
| Cash and cash equivalents | 22,917 | 16,657 | 40,388 | 55,728 | 38,214 | 53,888 | |||
| Short-term investments | 13,923 | 6,990 | 11,994 | 17,437 | 26,935 | ||||
| Other undisclosed cash, cash equivalents, and short-term investments | (17) | 20 | 22 | (22) | 49 | (23) | |||
| Receivables | 23 | 23 | 24 | 35 | 23 | 23 | |||
| Prepaid expense | 215 | 170 | 175 | 229 | 224 | 222 | |||
| Other current assets | 554 | 674 | 604 | 602 | 455 | 471 | |||
| Other undisclosed current assets | 5,371 | 5,841 | 7,307 | 8,332 | 7,162 | 6,878 | |||
| Total current assets: | 29,063 | 37,308 | 55,510 | 76,898 | 63,564 | 88,394 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 743 | 857 | 970 | 1,081 | 1,190 | 1,298 | |||
| Other undisclosed noncurrent assets | 198 | 198 | 199 | 199 | 199 | 200 | |||
| Total noncurrent assets: | 941 | 1,055 | 1,169 | 1,280 | 1,389 | 1,498 | |||
| TOTAL ASSETS: | 30,004 | 38,363 | 56,679 | 78,178 | 64,953 | 89,892 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6,649 | 8,675 | 12,332 | 13,963 | 7,162 | 13,448 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 1,484 | 1,052 | 707 | 2,779 | ||
| Accounts payable | 5,555 | 4,534 | 6,973 | 8,691 | 5,922 | 9,461 | |||
| Accrued liabilities | 1,094 | 4,141 | 3,875 | 4,220 | 533 | 1,208 | |||
| Other liabilities | 411 | 481 | 458 | 749 | 702 | 987 | |||
| Other undisclosed current liabilities | 26,191 | 24,268 | 33,724 | 37,003 | 14,353 | 12,027 | |||
| Total current liabilities: | 33,251 | 33,424 | 46,514 | 51,715 | 22,217 | 26,462 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 536 | 655 | 773 | 891 | |||||
| Liabilities, other than long-term debt | 291 | 414 | |||||||
| Operating lease, liability | 291 | 414 | 536 | 655 | 773 | 891 | |||
| Other undisclosed noncurrent liabilities | 534 | 464 | (536) | (655) | (773) | ||||
| Total noncurrent liabilities: | 825 | 878 | 536 | 655 | 773 | 891 | |||
| Total liabilities: | 34,076 | 34,302 | 47,050 | 52,370 | 22,990 | 27,353 | |||
| Equity | |||||||||
| Equity, attributable to parent | (4,072) | 4,061 | 9,629 | 25,808 | 41,963 | 62,539 | |||
| Common stock | 5 | 5 | 5 | 5 | 3 | 3 | |||
| Additional paid in capital | 354,883 | 352,828 | 343,995 | 341,090 | 331,476 | 328,958 | |||
| Accumulated other comprehensive income (loss) | 51 | 23 | 6 | (80) | (107) | ||||
| Accumulated deficit | (358,960) | (348,823) | (334,394) | (315,293) | (289,436) | (266,315) | |||
| Total equity: | (4,072) | 4,061 | 9,629 | 25,808 | 41,963 | 62,539 | |||
| TOTAL LIABILITIES AND EQUITY: | 30,004 | 38,363 | 56,679 | 78,178 | 64,953 | 89,892 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 10,660 | |||||||
| Gross profit: | 10,660 | |||||||
| Operating expenses | (21,518) | (18,972) | (19,356) | (21,521) | (23,101) | (27,114) | ||
| Operating loss: | (10,858) | (18,972) | (19,356) | (21,521) | (23,101) | (27,114) | ||
| Nonoperating income (expense) | 721 | 4,543 | 255 | (4,336) | (20) | (45) | ||
| Other nonoperating income (expense) | 31 | 17 | (8) | (90) | (96) | (279) | ||
| Loss from continuing operations: | (10,137) | (14,429) | (19,101) | (25,857) | (23,121) | (27,159) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (19,101) | (25,857) | (23,121) | (27,159) | |
| Net loss available to common stockholders, diluted: | (10,137) | (14,429) | (19,101) | (25,857) | (23,121) | (27,159) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2023 Q2 | 3/31/2023 Q1 | 12/31/2022 Q4 | 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (10,137) | (14,429) | (19,101) | (25,857) | (23,121) | (27,159) | ||
| Other comprehensive income (loss) | (51) | 28 | 17 | 86 | 27 | 147 | ||
| Comprehensive loss, net of tax, attributable to parent: | (10,188) | (14,401) | (19,084) | (25,771) | (23,094) | (27,012) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.